Mr. Qiu Dongfang

Mr. Qiu Dongfang (“Mr. Qiu”), aged 59, was appointed as the Chairman of the Board (“Chairman”) and Executive Director with effect from 9 September 2022. Served at the Technical Department of Ningbo Chemical Industry Bureau* (寧波化工局技術處) from 1985 to 1992 with his last position as director. From 1993 to 1997, Mr. Qiu served as the general manager of Shanghai Shenbiao Construction Engineering Co., Ltd.* (上海申標建築工程有限公司). From 1997 to 2015, Mr. Qiu served as the chairman and president of Shanghai Boill (Group) Co., Ltd.* (上海保集（集團）有限公司). Since 2015, Mr. Qiu has been serving as the chairman and president of Boill Holding Group Co., Ltd.* (保集控股集團有限公司), and he is currently also a director of Boill International Co., Limited (“Boill International”) and Liyao Investment Limited. Mr. Qiu graduated from Zhejiang Institute of Technology (浙江工學院) (currently known as Zhejiang University of Technology (浙江工業大學)) with a bachelor’s degree majoring in organic chemistry.

Mr. Zhang Sheng Hai

Mr. Zhang Sheng Hai (‘‘Mr. Zhang’’), aged 46, has been appointed as an executive Director with effect from 14 August 2017. Mr. Zhang holds a business administration diploma from China University of Geosciences and a business administration degree from Southwest University of Science and Technology. Mr. Zhang has over 10 years of experience in real estate industry and has extensive experience in construction and management of real estate development. He is currently the general manager of Nanchang Shenbiao Real Estate Development Co., Limited, a wholly owned subsidiary of Boill Holding Group. He joined Boill Holding Group in 1994 and served as deputy manager, manager and general manager for various subsidiaries of Boill Holding Group during the period from 1994 to 2016. Mr. Zhang has been a director for various subsidiaries of Boill Holding Group since 2016.

Mr. Qiu Bin

Mr. Qiu Bin (“Mr. Qiu”), aged 55, was appointed as a non-executive Director on 9 September 2022 and has been redesignated as an executive Director and the Chief Executive Officer with effect from 21 August 2023. Mr. Qiu holds a Master of Business Administration Degree from the City University of Macau. Mr. Qiu has over 30 years of experience in investment management and worked at various enterprises in Beijing, Shanghai and Shenzhen where he was responsible for project investment and assets restructuring. From January 2009 to October 2011, Mr. Qiu served as the general manager of China Technology Education Trust Association. Mr. Qiu also served various positions in companies the shares of which are listed on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”), including the chief executive officer of Sun Century Property Group Company Limited, a wholly-owned subsidiary of Suncity Group Holdings Limited (stock code: 1383) (“Sun City”)in November 2011 and an executive director of Sun City from June 2012 to July 2015; an executive director and the chief executive officer of Sheng Yuan Holdings Limited (stock code: 851) from July 2017 to January 2020; an executive director, chairman of the board and the chief executive officer of HongDa Financial Holding Limited (currently known as China Wood International Holding Co., Limited) (stock code: 1822) (“China Wood”) from March 2020 to December 2020; and an executive director of China Regenerative Medicine International Limited(stock code: 8158) from May 2020 to December 2020. Mr. Qiu has been serving as the chairman of Pacific Assets Alliance Limited since January 2013.

Mr. Chui Kwong Kau

Mr. Chui Kwong Kau (“Mr. Chui”), aged 56, has been appointed as a non-executive Director with effect from 6 March 2015. He has over 25 years of experience in financial management, accounting and auditing fields. Mr. Chui has been appointed as an executive director of Yuk Wing Group Holdings Limited (stock code: 1536) since 4 June 2021 and a non-executive director of Wan Kei Group Holdings Limited (stock code: 1718) since 7 January 2021, both being companies whose shares are listed on the Stock Exchange, and an executive director of Hong Kong Life Sciences and Technologies Group Limited (stock code: 8085, the securities of which had been listed on the GEM of the Stock Exchange until 14 September 2020) since 30 November 2009. Mr. Chui had been an independent non-executive director of Aurum Pacific (China) Group Limited (stock code: 8148) from 17 March 2010 to 16 March 2016, an executive director of China Energy Development Holdings Limited (stock code: 228) from 5 October 2005 to 30 June 2016 and a non-executive director of DeTai New Energy Group Limited (stock code: 559) from 1 December 2015 to 19 March 2020. Mr. Chui was an executive director of Ming Lam Holdings Limited (“Ming Lam Hldgs”) (former stock code: 1106) from 17 July 2019 to 14 August 2020. Mr. Chui was informed that Ming Lam Hldgs was ordered to be wound up by the High Court of Hong Kong on 31 August 2020. Mr. Chui was a non-executive director of Hsin Chong Group Holdings Limited (“HCGH”) (former stock code: 404) from 23 May 2015 to 29 March 2019 whose securities were listed on the main board of the Stock Exchange until 31 December 2019. HCGH was wound up by an order of the Supreme Court of Bermuda dated 20 January 2020. On 11 April 2022, the Listing Committee of the Stock Exchange issued a statement in relation to, among other things, public criticism of certain former members of the board of HCGH, details in respect of Mr. Chui (as a former nonexecutive director of such company) are set out in the Company’s announcement dated 19 April 2022.

Mr. Wang Zhe

Mr. Wang Zhe (‘‘Mr. Wang’’), aged 62, has been appointed as an independent non-executive Director with effect from 14 August 2017. He graduated from Southwestern University of Finance and Economic with a master’s degree in Business Administration. He is an economist and currently the secretary general for Association of Shanghai Internet Financial Industry, the vice chairman for Shanghai Financial Association and external supervisor of China Everbright Bank Company Limited (stock code: 6818). Since September 1985, Mr. Wang has served as the deputy section chief for the General Office of the People’s Bank of China, manager and general manager for the Shenzhen Branch of China Gold Coin Incorporation, vice president for the Shenzhen Branch of China CITIC Bank, deputy general manager for China Gold Coin Incorporation, general manager, director-general and party secretary for Shanghai Gold Exchange and the independent director of Shanghai Pudong Development Bank Co., Ltd. (a company whose shares are listed on the Shanghai Stock Exchange with stock code: 600000).

Mr. Chan Chi Keung, Billy

Mr. Chan Chi Keung (‘‘Mr. Chan’’), aged 49, has been appointed as an independent non-executive Director with effect from 15 November 2017. He graduated from Hong Kong Baptist University with an Honours Degree with major in Accounting. He is a fellow member of the Association of Chartered Certified Accountants. Mr. Chan has over 20 years’ experience in auditing, accounting and financial management. He is the financial controller, company secretary, and one of the authorised representatives of Changyou Alliance Group Limited (Stock Code 1039). He had worked in South China Media Group for 15 years from December 1999 to May 2015 and his last position was the deputy financial controller. He had worked in South China Assets Holdings Limited (formerly named as South China Land Limited and Capital Publications Limited, Stock Code 8155) from January 2004 to June 2008 as the qualified accountant and company secretary.

Mr. Yi Baxian

Mr. Yi Baxian (“Mr. Yi”), aged 57 , was appointed as a independent non-executive director with effect from 9 September 2022. Mr. Yi served as the general manager of the research and development department of Sinopharm Holding Co., Ltd. and the general manager of Sinopharm Holding Shenzhen Chinese Medicine Co., Ltd. during the period from October 2002 to September 2007. From September 2007 to December 2010, Mr. Yi served as the director at Sichuan Industrial Institute of Antibiotics* (四川抗菌素工業研究所). From December 2010 to July 2015, he served as the vice president (副院長) of China State Institute of Pharmaceutical Industry* (中國醫藥工業研究總院). From October 2013 to September 2015, Mr. Yi served as the chairman of Shanghai Yingkelong Pharmaceutical Development Co., Ltd.* (上海瀛科隆醫藥開發有限公司). From December 2013 to September 2015, he served as an executive director (常務理事長) at National (Shanghai) New Medicine Safety Evaluation Center* (國家（上海）新藥安全評價中心). From September 2015 to December 2021, he served as an independent director of Shanghai Medicilon Inc., a company the shares of which are since October 2019 listed on the Shanghai Stock Exchange (stock code: 688202). Since 2015, Mr. Yi has been serving as the managing partner and vice president of Shanghai Pudong Technology Investment Co., Ltd.* (上海浦東科技投資有限公司). Mr. Yi graduated China Pharmaceutical University (中國藥科大學) with a bachelor’s degree in pharmacy (生藥製藥本科), and subsequently obtained a master’s degree from Shaanxi Master of Business Administration Institute* (陝西工商管理碩士學院) and a doctoral degree in social and management pharmacy from China Pharmaceutical University.